Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710756 · ClinicalTrials.gov registry record · Phase 1
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Perspective Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 3
- Study locations
NCT06710756: Recruiting Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Perspective Therapeutics.
NCT06710756 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Perspective Therapeutics. The registered enrollment target is 112 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710756, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Perspective Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Primary Outcome
Incidence and severity of treatment-related adverse events following a single administration of \[203Pb\]Pb-PSV359 is determined
Conditions Studied
Interventions
- DRUG [203Pb]Pb-PSV359
- DRUG [212Pb]Pb-PSV359
Study Locations (3)
Missouri
- Saint Louis University - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2032-05-28 |
| Phase | Phase 1 |
What NCT06710756 shows while recruiting
NCT06710756 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower).
The record links to 8 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]Pb-PSV359 is the first listed.
NCT06710756 reports a single indexed study location in Missouri, Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06710756 about?
NCT06710756 is a clinical study titled "Lead-212 PSV359 Therapy for Patients With Solid Tumors". Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
What is the current status of trial NCT06710756?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-04-28. Estimated completion is 2032-05-28.
What conditions does trial NCT06710756 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT06710756?
The interventions under investigation include: [203Pb]Pb-PSV359 (DRUG), [212Pb]Pb-PSV359 (DRUG).
Who is sponsoring clinical trial NCT06710756?
This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710756 being conducted?
This trial has 3 study locations across Missouri, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06710756's enrollment target sits among peer trials
112 208th of 381 higher than 173 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI